RMC No. 119-2022 adds Nirmatrelvir + Ritonavir 150 mg + 100 mg tablets for COVID-19 to the VAT-exempt list, effective from FDA publication, impacting healthcare providers and distributors.

Businesses and healthcare providers must update their VAT-exempt inventory immediately: the Food and Drug Administration has added Nirmatrelvir + Ritonavir 150 mg + 100 mg film-coated tablets to the official list of VAT-exempt medicines under the CREATE Act. This means sales of this medicine for COVID-19 treatment are now exempt from the 12% value-added tax effective from the FDA’s publication date.

What Changed

RMC No. 119-2022, issued on August 8, 2022, incorporates the July 20, 2022 FDA letter endorsing the inclusion of the Nirmatrelvir + Ritonavir 150 mg + 100 mg tablet as a VAT-exempt medicine. This updates the List of VAT-Exempt Medicines under Republic Act No. 11534 (CREATE Act). Previously, COVID-19 treatment medicines were covered only if specified in the existing list; the addition expands the exemption to include this newly recognized therapy.

Who is Affected

Pharmaceutical companies, drug distributors, hospitals, clinics, and other healthcare providers that sell or dispense this medicine are directly impacted. Additionally, accounting and finance teams responsible for VAT reporting must adjust systems to ensure proper exemption handling. Importers and wholesalers should also update their compliance records.

Key Compliance Requirements

VAT exemption for this medicine takes effect on the date of FDA publication, as clarified under Q&A No. 1 of RMC No. 99-2021. Businesses must:

– Update invoicing and accounting systems to correctly mark Nirmatrelvir + Ritonavir 150 mg + 100 mg as VAT-exempt.
– Maintain documentation of FDA publication and endorsement for audit purposes.
– Ensure that VAT reporting reflects the exempt status to avoid penalties for misclassification.

Penalties for Non-Compliance

Failing to apply the VAT exemption properly may lead to assessment of erroneously collected VAT, including interest and surcharges. Companies may also be subject to administrative penalties under the National Internal Revenue Code if records fail to substantiate the VAT-exempt treatment of the medicine.

Practical Steps

Pharmaceutical and healthcare businesses should immediately communicate the update to accounting and inventory teams. Update billing templates, point-of-sale systems, and internal procedures to reflect the exemption. Keep a copy of the FDA letter and RMC No. 119-2022 for documentation. Consider staff training or notices to ensure frontline personnel correctly apply the VAT exemption during sales and dispensing.

For comprehensive compliance review and guidance on implementing these VAT exemptions, contact Ablola, Saribong & Gueco. Our team of experts ensures your business aligns with all current BIR rules. Visit MakatiLawFirm.com to schedule a consultation today.


Leave a Comment

Your email address will not be published. Required fields are marked *